The big drugmakers — companies that develop and manufacture prescription pills and medicines you pick up at the pharmacy, like painkillers and blood-pressure drugs.
Contains
News movingPharmaceuticals
China
Pharmaceuticals▼
Harbin Pharmaceutical Group Director and President Lu Chuanyou Placed on File for Investigation and Subject to Detention
Harbin Pharmaceutical Group announced that the company recently received a Notice of Case Filing and a Notice of Detention from the relevant supervisory committee regarding company director and president Lu Chuanyou. The company stated that it has made proper arrangements for related work, and that the chairman, other directors, and other senior management are all performing their duties normally, with the board of directors operating as usual.
600664.CG · Regulation · Negative Director and president Lu Chuanyou placed on file for investigation and subject to detention by supervisory authorities.
Harbin Pharmaceutical Group Director and President Lu Chuanyou Placed Under Detention
Harbin Pharmaceutical Group announced on October 11 that the company recently received a case filing notice and a detention notice from the relevant supervisory committee regarding Lu Chuanyou, a director and president of the company. The company stated that it has made proper arrangements for related work, and that the chairman, other directors, and other senior management are performing their duties normally, with the board operating normally and production and operations proceeding as usual. The announcement said the above matter will not have a significant impact on the company's production, operations, or management.
600664.CG · Regulation · Negative Director and president Lu Chuanyou placed under detention by a supervisory committee, a legal/regulatory action against the company's leadership.
Haisco Elects Wang Junmin as Chairman and Appoints Yan Pangke as General Manager
Haisco announced that the first meeting of the company's sixth board of directors elected Wang Junmin as chairman. The meeting also appointed Yan Pangke as general manager, Wang Meng as deputy general manager and board secretary, Duan Peng as chief financial officer, and Guo Yan as securities affairs representative.
002653.CS · · Neutral Board elects Wang Junmin as chairman and appoints Yan Pangke as general manager; routine corporate governance changes with no clear operational or financial driver.
Jinghua Pharmaceutical's Ji Desheng Snake Tablet Gains Clinical Trial Approval for New Shingles Indication
Jinghua Pharmaceutical announced on October 11 that it recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration. The clinical trial application for its Ji Desheng Snake Tablet to add a new indication for shingles, specifically the liver-gallbladder damp-heat syndrome, has been approved. Ji Desheng Snake Tablet is a marketed traditional Chinese medicine product of the company, with current approved indications being clearing heat and detoxifying, reducing swelling and relieving pain, for use in venomous snake and insect bites.
002349.CS · Technology · Positive Ji Desheng Snake Tablet received NMPA clinical trial approval to add a new shingles indication, an R&D/product development for the company.
Harbin Pharmaceutical Group President Lu Chuanyou Detained; Company Says Operations Not Significantly Affected
Harbin Pharmaceutical Group announced on October 11 that director and president Lu Chuanyou recently received a case filing notice and a detention notice from the relevant supervisory committee. The company said it has made proper arrangements for related work, the chairman, other directors and senior management are performing their duties normally, and the board of directors is operating normally. The announced matter will not have a significant impact on the company's production, operation and management. In the first half of 2026, Harbin Pharmaceutical Group achieved revenue of 8.296 billion yuan and net profit attributable to the parent of 410 million yuan.
600664.CG · Regulation · Negative Director and president Lu Chuanyou was detained by a supervisory committee, a legal/regulatory action against the company's leadership.
Harbin Pharmaceutical's 64-year-old president Lu Chuanyou placed under investigation and detention, earned 2.9668 million yuan last year
Harbin Pharmaceutical announced on October 11 that the company recently received a case filing notice and a detention notice from the relevant supervisory committee regarding its director and president Lu Chuanyou. Harbin Pharmaceutical said it has made proper arrangements for related work, and that the chairman, other directors, and other senior managers are all performing their duties normally. The board of directors is operating normally, and production and operations are normal. The matters in the announcement will not have a material impact on the company's production, operations, or management. According to Harbin Pharmaceutical's 2025 annual report, Lu Chuanyou is 64 years old. He previously served as chief engineer, executive deputy factory director, factory director, and party secretary of Harbin Pharmaceutical Group No. 6 Pharmaceutical Factory, party secretary, chairman, and general manager of Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd., and vice president and senior advisor of the company. He currently serves as a member of the company's party committee, a director of the 10th board of directors, a member of the board's strategy and sustainable development committee, and president. In 2025, he received a salary of 2.9668 million yuan. Harbin Pharmaceutical focuses on the pharmaceutical and health industry, mainly engaged in pharmaceutical research and development, manufacturing, wholesale, and retail. In the first half of this year, the company achieved operating revenue of 8.296 billion yuan, an increase of 2.10 percent year on year. Net profit attributable to shareholders of the listed company was 410 million yuan, an increase of 57.99 percent year on year. Net profit attributable to shareholders of the listed company after deducting non-recurring items was 355 million yuan, an increase of 45.39 percent year on year. Basic earnings per share were 0.1629 yuan.
600664.CG · Regulation · Negative President and director Lu Chuanyou placed under investigation and detained by supervisory committee, a legal/regulatory action against a top executive.
Jinghua Pharmaceutical's Ji Desheng Sheyao Tablets Gain Clinical Trial Approval for New Shingles Indication
Jinghua Pharmaceutical announced on October 11 that it recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving clinical trials for Ji Desheng Sheyao Tablets to add a new indication for shingles, specifically the liver-gallbladder damp-heat syndrome. The application was accepted on July 17, 2026, and the review conclusion agreed to conduct the relevant clinical trials, with the approval date being October 8, 2026. Ji Desheng Sheyao Tablets are already on the market, with current approved functions of clearing heat, detoxifying, reducing swelling, and relieving pain, used for venomous snake and insect bites. The clinical trials for this new indication will proceed with Phase II and Phase III trials according to the general principles of drug development to verify its clinical value. The company stated that this approval will not have a significant impact on current operating performance, but drug development is characterized by high investment, long cycles, and high risk, and future market competition and research outcomes remain uncertain. In the first half of 2026, Jinghua Pharmaceutical achieved revenue of 755 million yuan and net profit attributable to the parent company of 136 million yuan.
002349.CS · Technology · Positive Received NMPA clinical trial approval to add a new shingles indication for Ji Desheng Sheyao Tablets, advancing its R&D pipeline.
Haixin Shares' largest shareholder Ningrui Investment plans public solicitation to transfer part of its stake, possibly leading to a change in the largest shareholder
Haixin Shares announced on October 11 that its largest shareholder, Hunan Ningrui Investment Partnership, and its concert party, Hunan Caixin Economic Investment Co., Ltd., together hold 14.98% of the company's equity. Ningrui Investment plans to transfer part of the company's shares through public solicitation of transferees. This matter may lead to a change in the company's largest shareholder.
600851.CG · Capital · Neutral Largest shareholder Ningrui Investment plans a public solicitation to transfer part of its stake, possibly changing the largest shareholder.
Hunan Ningrui Investment Partnership · Capital · Neutral Ningrui Investment is the largest shareholder planning to transfer part of its Haixin Shares stake via public solicitation.
Hunan Caixin Economic Investment · Capital · Neutral Caixin Economic Investment is a concert party of Ningrui Investment, which plans the stake transfer.
Haisco Plans to Provide Up to 165 Million Yuan Loan to Controlling Subsidiary Haisijieyin
Haisco announced on October 11 that it plans to provide financial assistance in the form of a loan using its own funds to its controlling subsidiary Haisijieyin, with the amount not exceeding 165 million yuan. Haisijieyin's minority shareholder Hailikesi will provide financial assistance under the same conditions in proportion to its capital contribution, with the amount not exceeding 18.97 million yuan. The annualized interest rate of the loan is 3.05 percent, and the loan facility is valid for five years. Haisijieyin needs to draw down the funds in installments according to its capital usage plan, and any single loan must be fully repaid by the end of the five-year period. This financial assistance is intended to promote the business development of Haisijieyin and supplement its working capital, and will not affect the company's normal business operations. In the first half of 2026, Haisco achieved revenue of 3.096 billion yuan and net profit attributable to the parent company of 851 million yuan.
002653.CS · Capital · Positive Haisco provides a 165 million yuan loan to its controlling subsidiary Haisijieyin to supplement working capital and support business development.
Helix (Chengdu) Pharmaceutical Technology Co., Ltd. · Capital · Positive Haisijieyin receives up to 165 million yuan in financial assistance from parent Haisco, supplementing its working capital.
Harbin Pharmaceutical Group Director and President Lu Chuanyou Placed on File and Subject to Detention
Harbin Pharmaceutical Group announced that the company recently received a Notice of Filing and a Notice of Detention from the relevant supervisory committee regarding company director and president Lu Chuanyou. The company stated that it has made proper arrangements for related work, and that the chairman, other directors, and other senior management are all performing their duties normally, with the board of directors operating as usual.
600664.CG · Regulation · Negative Director and president Lu Chuanyou placed on file and subject to detention by supervisory committee, a legal/regulatory action against a top executive.
Haixin Co.'s largest shareholder Ningrui Investment plans to transfer 10% stake via public solicitation
Haixin Co. announced on October 11 that its largest shareholder, Hunan Ningrui Investment Partnership, and its concert party Hunan Caixin Economic Investment Co., Ltd. together hold 14.98% of the company's equity. Ningrui Investment holds 142 million shares, accounting for 11.73% of total share capital, while Caixin Economic Investment holds 39.29 million shares, accounting for 3.25%. Ningrui Investment plans to transfer 121 million unrestricted tradable shares, representing 10% of the company's total share capital, through public solicitation of a transferee. This matter may lead to a change in the company's largest shareholder. The public solicitation transfer still needs approval from the state-owned assets supervision and administration authority or other competent institutions before it can be implemented. Whether approval can be obtained and the timing of approval remain uncertain, and the transferee also remains uncertain before completion of the public solicitation transfer procedures. Specific information such as the timing of the public solicitation and transferee qualification requirements will be disclosed by the company later. In the first half of 2026, Haixin Co. achieved revenue of 312 million yuan and net profit attributable to the parent company of 129 million yuan.
600851.CG · Capital · Neutral Largest shareholder plans to transfer 10% stake via public solicitation, potentially changing the largest shareholder, but approval and transferee remain uncertain.
Hunan Ningrui Investment Partnership · Capital · Neutral Ningrui Investment is the seller transferring 121 million shares (10% stake) through public solicitation, with outcome uncertain.
Hunan Caixin Economic Investment · Capital · Neutral Concert party of the largest shareholder holding 3.25%; its stake is context for the planned 10% transfer, no independent development.
Harbin Pharmaceutical Director and President Lu Chuanyou Placed on File and Subject to Detention
Harbin Pharmaceutical announced on the evening of October 11 that the company recently received a Notice of Case Filing and a Notice of Detention from the relevant supervisory committee regarding company director and president Lu Chuanyou. According to an announcement disclosed by the company at the end of August, the 2026 interim results briefing scheduled for September 10, 2026, still included director and president Lu Chuanyou among the participants. Lu Chuanyou previously served as chief engineer, executive deputy factory director, factory director, and party secretary of Harbin Pharmaceutical Group No. 6 Pharmaceutical Factory, party secretary, chairman, and general manager of Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd., and deputy general manager of Harbin Pharmaceutical Group Co., Ltd. Since 2023, he has served as president and member of the strategy committee of Harbin Pharmaceutical Group Co., Ltd. Harbin Pharmaceutical stated that the company has a sound organizational structure and a standardized governance system, has made proper arrangements for related work, and that the chairman, other directors, and other senior management are performing their duties normally. The board of directors is operating normally, production and operations are normal, and the announced matter will not have a material impact on the company's production, operations, or management. The company's 2026 interim report showed that first-half operating revenue reached 8.296 billion yuan, up 2.10 percent year on year; net profit attributable to shareholders of the listed company reached 410 million yuan, up 57.99 percent year on year; and net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses reached 355 million yuan, up 45.39 percent year on year.
600664.CG · Regulation · Negative Director and president Lu Chuanyou placed on file and subject to detention by supervisory authorities, a legal/regulatory action against a top executive.
Haixin Co.'s largest shareholder Ningrui Investment plans to publicly solicit transfer of 10% stake
Haixin Co. announced that its largest shareholder Ningrui Investment plans to transfer 121 million unrestricted tradable shares, representing 10% of the company's total share capital, through public solicitation of transferees. The announcement shows that upon completion of this transfer, it may lead to a change in the company's largest shareholder.
600851.CG · Capital · Neutral Largest shareholder Ningrui Investment plans to transfer 10% of Haixin's shares via public solicitation, potentially changing the largest shareholder.
Hunan Ningrui Investment Partnership · Capital · Neutral Ningrui Investment, Haixin's largest shareholder, plans to publicly solicit transfer of its 10% stake, potentially ending its position as largest shareholder.
Merck's Remigromig Meets Primary Endpoint in Pivotal BRUNELLO DME Trial
Merck announced that remigromig, an investigational tri-specific antibody that activates the Wnt pathway, met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema, with both dose arms demonstrating non-inferiority in mean change from baseline in best corrected visual acuity at one year versus monthly 0.5mg ranibizumab. Mean BCVA gains at Year 1 were +9.1 letters with remigromig 0.5 mg and +8.7 letters with remigromig 0.8 mg, compared with +11.8 letters with ranibizumab, and no secondary endpoints demonstrated superiority to ranibizumab. The company said remigromig is the first biologic with a novel mechanism of action to demonstrate non-inferior visual acuity compared with anti-VEGF therapy in a pivotal DME trial, and the first new mechanism of action in more than 20 years to do so. Adverse events related to proliferative diabetic retinopathy occurred more frequently with remigromig than with ranibizumab, at 6.7% and 6.1% for the 0.5 mg and 0.8 mg arms versus 0.9%, and treatment discontinuations due to adverse events were also higher, at 4.9% and 4.5% versus 0.9%. The results, presented at the American Academy of Ophthalmology 2026 Annual Meeting in New Orleans, will be discussed with regulatory authorities, and remigromig is also being evaluated in the ongoing pivotal Phase 2b/3 BAROLO study in DME and a Phase 2 proof-of-concept study in NVAMD and RVO.
MRK.XETRA · Technology · Positive Remigromig met the primary endpoint in the pivotal BRUNELLO DME trial, a positive R&D/clinical result for Merck KGaA.
Roche's vamikibart shows one-year vision gains in uveitic macular edema as FDA accepts BLA
Roche announced new one-year data from the Phase III MEERKAT and SANDCAT studies showing that investigational vamikibart sustained improvements in vision and reductions in macular thickness in adults with uveitic macular edema at 52 weeks compared with a sham procedure. The results were presented at the American Academy of Ophthalmology 2026 Annual Meeting in New Orleans. The FDA has accepted Roche's Biologics License Application for vamikibart for the treatment of UME, with an approval decision expected by July 2027; if approved, vamikibart would be the first non-steroid targeted treatment for UME. Regulatory submissions have also been filed and accepted in the European Union, China and Japan. In both trials, a numerically higher proportion of vamikibart-treated patients achieved vision gains than those on sham treatment on the primary endpoint, and key secondary endpoints showed sustained improvements in best corrected visual acuity and central subfield thickness. Vamikibart was well tolerated with a low incidence of treatment-related ocular adverse events and intraocular inflammation events, and approximately two-thirds of eligible patients required no retreatment after 16 weeks.
Schneider Electric to buy PTC for $22.6 billion as deal wave sweeps sectors
Schneider Electric SE agreed to acquire U.S.-based engineering software developer PTC Inc. for $22.6 billion, or €20.1 billion, paying $205 per share in an all-cash deal. The transaction was among a string of major deals reported across sectors this week. Viatris said it will acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, while CD&R and McKesson agreed to acquire Option Care Health for $32.05 per share, valuing it at approximately $5.8 billion including debt, sending its shares up 34% in early trading Tuesday. Energy Transfer agreed to acquire Vaquero Midstream in a $2.625 billion deal consisting of $1.95 billion in cash and about 33.3 million newly issued Energy Transfer common units, and Cenovus Energy agreed to acquire Athabasca Oil in a cash-and-stock deal valued at about C$5.7 billion, a 14% premium to Athabasca's 20-day volume-weighted average trading price. Canadian utilities Emera and Canadian Utilities agreed to an all-stock merger worth C$14.3 billion, or US$10 billion, creating a combined company with a C$72 billion enterprise value and a regulated rate base of C$45 billion serving roughly 6 million customers. Separately, TKO LLC proposed to acquire Service Properties Trust's entire hospitality portfolio for $2.0 billion, and CCC Intelligent Solutions soared 13% in after-hours trading on a report that GTCR and Elliott Investment Management are in advanced discussions to purchase the car-insurance software firm.
CCC · Capital · Positive CCC Intelligent Solutions soared 13% after-hours on a report that GTCR and Elliott are in advanced talks to acquire the firm.
CVE · Capital · Positive Cenovus Energy agreed to acquire Athabasca Oil in a cash-and-stock deal valued at about C$5.7 billion.
EMA · Capital · Positive Emera agreed to an all-stock merger with Canadian Utilities worth C$14.3 billion, creating a combined utility with a C$72 billion enterprise value.
ET · Capital · Positive Energy Transfer agreed to acquire Vaquero Midstream for $2.625 billion in cash and newly issued common units.
MCK · Capital · Positive McKesson, with CD&R, agreed to acquire Option Care Health for $32.05 per share, valuing it at about $5.8 billion including debt.
OPCH · Capital · Positive CD&R and McKesson agreed to acquire Option Care Health for $32.05 per share, a takeover deal that lifts its shares.
AstraZeneca Launches AI Biologics Discovery Tie-Up With Carterra
AstraZeneca has launched a new AI-driven biologics discovery collaboration with Carterra, announced ahead of trading on 9 October 2026. The partnership links AstraZeneca's AI models with Carterra's high-throughput biosensor instruments to create autonomous, lab-in-the-loop discovery workflows. The project focuses on large molecule biologics, aiming to shorten experimental decision cycles and scale up antibody and protein engineering campaigns. AstraZeneca, which operates at a £186.1 billion market cap scale, is betting that the tie-up supports the premise that heavier spending on technologies like AI will translate into faster, more targeted drug launches and stronger earnings power. The unresolved question is whether such AI collaborations can offset pressure from patent expiries, price controls and high core R&D spend, especially as competitors like Pfizer and Merck also wire AI into their discovery lines.
AZN.LSE · Technology · Positive AstraZeneca launched an AI-driven biologics discovery collaboration with Carterra to speed antibody and protein engineering.
Carterra · Demand · Positive Carterra's biosensor instruments are being adopted in AstraZeneca's AI biologics discovery partnership.
LB Pharmaceuticals Presents Preclinical Data on LB-102 Mechanism at ECNP Congress
LB Pharmaceuticals announced the presentation of four posters at the 39th European College of Neuropsychopharmacology Congress in Munich, Germany, running October 10-13, 2026. The posters cover new preclinical data on LB-102's differentiated mechanism of action, the pivotal Phase 3 program in schizophrenia known as NOVA-2 and NOVA-3, the ongoing late-stage Phase 2 ILLUMINATE-1 trial in bipolar depression, and a previously reported analysis of LB-102's impact on cognitive performance from the Phase 2 NOVA-1 trial in schizophrenia. The preclinical data showed that LB-102 can modulate dopamine signaling through engagement of pre-synaptic D2 autoreceptors, increasing dopamine neurotransmission, which the company said supports a potential mechanism for addressing the hypodopaminergic state associated with anhedonia and diminished motivation in depression. A post hoc analysis of the Phase 2 NOVA-1 trial found that the dose-dependent, statistically significant improvements in cognitive performance were primarily a direct effect of LB-102 rather than an indirect consequence of the drug's effect on total schizophrenia symptoms. LB-102 is a novel, once-daily, orally administered investigational small molecule engineered as a modification to amisulpride, and the company believes it has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
LBRX · Technology · Positive Presented preclinical data on LB-102's differentiated mechanism and Phase 2/3 trial results supporting its antipsychotic and cognitive effects.
Shengnuo Bio's actual controller and subsidiary sued over bid-rigging in the seventh national drug procurement round
Shengnuo Bio announced on the evening of October 9 that its wholly owned subsidiary Shengnuo Pharmaceutical and actual controller Wen Yongjun had received an indictment issued by the People's Procuratorate of Yuhuatai District, Nanjing, Jiangsu Province. According to the prosecution opinion from the Yuhuatai branch of the Nanjing Public Security Bureau, Shengnuo Pharmaceutical is suspected of participating in bid-rigging for octreotide acetate injection in the seventh national centralized drug procurement round. Relevant personnel promised benefits, and Shengnuo Pharmaceutical actually won the bid as the fifth-ranked bidder, with illegal gains of 10.98 million yuan during the contract period. The Yuhuatai procuratorate believes that Shengnuo Pharmaceutical and Wen Yongjun colluded with other companies and individuals in submitting bid prices during the seventh national centralized drug procurement round, harming the interests of the tenderer or other bidders, with serious circumstances, violating Article 223, Paragraph 1 of the Criminal Law of the People's Republic of China. The criminal facts are clear and the evidence is reliable and sufficient, so criminal liability for the crime of bid-rigging should be pursued. Shengnuo Bio stated that Wen Yongjun is still performing his duties normally while released on bail pending trial, and the company has made a provision for the above 10.98 million yuan in illegal gains in its 2025 financial statements, which is expected to affect net profit attributable to the parent company this year or in future years. In the first half of this year, the company achieved revenue of 507 million yuan, up 50.27 percent year on year, and net profit attributable to the parent company of 135 million yuan, up 51.98 percent year on year.
688117.CG · Regulation · Negative Subsidiary and actual controller indicted for bid-rigging in the seventh national drug procurement round, with 10.98 million yuan illegal gains provisioned and potential criminal liability.
Jingxin Pharmaceutical Files for Hong Kong Listing a Second Time, Holding 2.385 Billion Yuan in Cash, Sparking Debate Over Fundraising Necessity
Jingxin Pharmaceutical has recently updated its H-share listing application with the Hong Kong Stock Exchange, with CITIC Securities acting as the sole sponsor. This marks the company's second submission of listing materials to the main board of the Hong Kong Stock Exchange, following the lapse of its first filing in February 2026 after the six-month validity period expired. The Hong Kong fundraising is earmarked for four main purposes: new drug research and development, market channel expansion, industrial mergers and acquisitions and cooperation, and general working capital. However, the company has not disclosed the specific proportion of investment for each direction, nor has it disclosed details of the corresponding research and development pipeline. Financial data shows that as of the end of 2025, the company's cash-like assets totaled as much as 2.385 billion yuan, while interest-bearing liabilities in the same period were only 215 million yuan in short-term borrowings, with no long-term debt pressure. From 2023 to 2025, operating cash flow amounted to 793 million yuan, 726 million yuan, and 781 million yuan respectively. In 2025, the company implemented cash dividends of 287 million yuan and share repurchases of 609 million yuan, with the combined amount of dividends and repurchases accounting for 118.21 percent of the net profit attributable to the parent company for that year. At the same time, the company's research and development expenses have declined for three consecutive years, falling from 401 million yuan to 383 million yuan, and further dropping to 368 million yuan. The proportion of research and development investment to revenue also decreased from 10.0 percent to 9.0 percent. In the first half of 2026, research and development expenses fell 10.89 percent year-on-year, with the revenue share further declining to 8.3 percent. Revenue for the period was 1.987 billion yuan, down 1.46 percent year-on-year, and net profit attributable to the parent company was 352 million yuan, down 9.35 percent year-on-year. The prospectus discloses that the utilization rate of the company's core generic drug production lines fell from 77 percent in 2023 to 61.3 percent in the first half of 2026, while the utilization rate of traditional Chinese medicine production lines dropped from 55.6 percent to 24.9 percent. As the core asset of the company's transformation and innovation, the only approved Class 1 innovative drug, Dimdazenil, under the trade name Jingnuoning, was approved for marketing in November 2023 and included in the national medical insurance catalog in November 2024. However, this product was not independently developed but is a licensed-in variety. Jingxin Pharmaceutical obtained the development and commercialization rights in China through a licensing agreement in 2010. The fastest-progressing candidate in the research pipeline is JX2201, targeting the Lp(a) cardiovascular target, which has obtained an Investigational New Drug approval in the United States but has not yet initiated overseas clinical trials. The Phase I clinical trial in China has been completed, and Phase II dose exploration studies are currently being advanced.
002020.CS · Capital · Neutral Jingxin refiles for a Hong Kong H-share listing to raise funds for R&D, channel expansion, M&A and working capital, despite holding 2.385 billion yuan in cash and no long-term debt, sparking debate over the necessity of fundraising.
Hisun Pharmaceutical's Controlling Subsidiary Obtains Veterinary Drug Approval for Telmisartan for Cats
Hisun Pharmaceutical announced that its controlling subsidiary, Hisun Animal Health, recently received the veterinary drug product approval number for telmisartan oral solution for cats, approved by the Ministry of Agriculture and Rural Affairs. The approval is valid from October 8, 2026 to October 7, 2031, with a specification of 30 milliliters to 0.12 grams. The product is used to treat proteinuria caused by chronic kidney disease in cats, and will help enrich the company's pet drug product line.
600267.CG · Regulation · Positive Controlling subsidiary Hisun Animal Health received veterinary drug approval for telmisartan oral solution for cats, enriching its pet drug product line.
Shengnuo Bio subsidiary and actual controller prosecuted for bid-rigging, with illegal gains of 10.9796 million yuan
Shengnuo Bio announced on the evening of October 9 that its wholly owned subsidiary Chengdu Shengnuo Biopharmaceutical Co., Ltd. and actual controller Wen Yongjun had received an indictment from the People's Procuratorate of Yuhuatai District, Nanjing, Jiangsu Province, on suspicion of bid-rigging, with illegal gains of 10.9796 million yuan. According to the announcement, Shengnuo Pharmaceutical is suspected of participating in bid-rigging for the drug octreotide acetate injection in the seventh national volume-based procurement program. Relevant personnel promised, and Shengnuo Pharmaceutical actually won the bid as the fifth-ranked bidder, with illegal gains of 10.9796 million yuan during the contract period. Shengnuo Pharmaceutical sold 7.5107 million units of the injection, with sales amounting to 117 million yuan. Wen Yongjun was released on bail pending trial by the Yuhuatai branch on December 18, 2024, on suspicion of bid-rigging, and was again released on bail pending trial by the Yuhuatai procuratorate on December 17, 2025. He is still performing his duties normally. The procuratorate holds that this case constitutes a joint crime and a unit crime, and that Wen Yongjun, as the directly responsible person in charge, is the principal offender. However, because he surrendered voluntarily and truthfully confessed his crimes, he is considered to have turned himself in and may be given a lighter punishment. The company has already made a provision for the illegal gains of 10.9796 million yuan as an estimated liability in its 2025 financial statements. Because the amount of the fine is not yet determined, it is expected to affect the net profit attributable to shareholders of the listed company for this year or future years.
688117.CG · Regulation · Negative Wholly owned subsidiary and actual controller indicted for bid-rigging in national procurement, with illegal gains of 10.9796 million yuan and potential fines affecting net profit.
成都圣诺生物制药有限公司 · Regulation · Negative The subsidiary itself is prosecuted for bid-rigging the octreotide acetate injection in the seventh national volume-based procurement, with 10.9796 million yuan in illegal gains.
Shengnuo Bio subsidiary and actual controller prosecuted over bid-rigging in seventh national drug procurement round, with illegal gains of 10.9796 million yuan
Shengnuo Bio announced on the evening of October 9 that its wholly owned subsidiary Chengdu Shengnuo Biopharmaceutical Co., Ltd. and actual controller and chairman Wen Yongjun recently received an indictment from the People's Procuratorate of Yuhuatai District, Nanjing, Jiangsu Province, for alleged collusive bidding in the seventh national centralized drug procurement round, with illegal gains of 10.9796 million yuan. According to the prosecution opinion from the Yuhuatai branch of the Nanjing Public Security Bureau, Shengnuo Pharmaceutical is suspected of participating in bid-rigging for octreotide acetate injection in the seventh procurement round. Relevant personnel made commitments, and Shengnuo Pharmaceutical actually won the bid in fifth place, with illegal gains of 10.9796 million yuan during the contract period. Wen Yongjun was released on bail pending trial by the Yuhuatai branch on December 18, 2024, on suspicion of bid-rigging, and was again released on bail by the Yuhuatai procuratorate on December 17, 2025. He continues to perform his duties normally during the bail period. The company has already recognized a provision for the above 10.9796 million yuan in illegal gains in its 2025 financial statements. The subsequent fine amount will be determined after the case is concluded by the People's Court of Yuhuatai District, Nanjing, Jiangsu Province, and is expected to affect the company's net profit attributable to shareholders of the listed company for this year or future years. In the first half of 2026, Shengnuo Bio achieved operating revenue of 507 million yuan, up 50.27 percent year on year, and net profit attributable to shareholders of the listed company of 135 million yuan, up 51.98 percent year on year.
688117.CG · Regulation · Negative Wholly owned subsidiary and chairman indicted for bid-rigging in national drug procurement, with 10.98M yuan illegal gains and potential fines hitting net profit.
成都圣诺生物制药有限公司 · Regulation · Negative Shengnuo Pharmaceutical is the subsidiary prosecuted for collusive bidding on octreotide acetate injection in the seventh procurement round.
UBS Cuts PolyPeptide Group to Neutral After Samsung Biologics Tender Offer
UBS downgraded PolyPeptide Group to neutral following Samsung Biologics' all cash tender offer, shifting investor focus toward deal completion rather than further upside. PolyPeptide shares trade at CHF43.85, close to both the UBS target and Samsung's offer, after an 82.71% share price return and an 81.20% total shareholder return over one year, though the 5 year total shareholder return remains down 63.39%. The most followed narrative pegs fair value at CHF39.09, implying the stock is 12% overvalued, based on a discount rate of 4.89%. The peptide therapeutics market is expected to grow more than 15% annually with nearly 500 drugs in late stage development, but PolyPeptide could struggle to convert its Phase III exposure into sustained commercial wins if programs are delayed or terminated, pressuring revenue growth and EBITDA progression.
PPGN.SW · Capital · Neutral UBS downgraded PolyPeptide to neutral after Samsung Biologics' tender offer, with shares near the offer price and fair value seen 12% overvalued
207940.KO · Capital · Positive Samsung Biologics' all-cash tender offer for PolyPeptide is an M&A move that expands its peptide business
Bayer Wins FDA Acceptance for KERENDIA CKD Filing Without Diabetes
Bayer reported that the U.S. FDA accepted its supplemental New Drug Application for KERENDIA for chronic kidney disease patients without diabetes. The filing is backed by Phase III trial data that Bayer says showed kidney and cardiovascular benefits in non diabetic CKD patients, and KERENDIA is already approved in the U.S. for adults with chronic kidney disease associated with type 2 diabetes. The sNDA covers adults with CKD without diabetes on standard care, a population not included in KERENDIA's current U.S. approvals, and the FIND CKD trial enrolled 1,584 such patients and showed a statistically significant 0.7 mL/min/1.73 m²/year difference in eGFR decline versus placebo, plus a benefit on a kidney cardiovascular composite outcome. Bayer, a €41.8 billion life science group active across Europe, the Americas and Asia, has been pushing deeper into prescription therapies, and the company's narrative highlights new labels and approvals for KERENDIA as a key pharmaceutical catalyst that can help offset patent losses. The critical signpost now is the FDA's decision on this sNDA, including the timing and any label wording around the kidney and cardiovascular endpoints from FIND CKD.
GSK to invest over $800M in Pennsylvania expansion, adding 300 jobs
GSK will expand its Pennsylvania operations with a more than $800M investment in Montgomery County, a move expected to add roughly 300 jobs over the next five years. The pharma company already employs about 4,500 full-time workers in the state. The expansion, set to begin next year in Upper Merion Township, will involve demolishing current buildings and constructing new ones, including a commercial-scale biologics manufacturing facility, an R&D pilot plant, a centralized quality control lab, and a manufacturing science and technology hub. The new investment follows an October 2024 announcement of an up to $800M commitment to boost R&D and manufacturing at a facility in Lancaster County.
GSK.LSE · Capital · Positive GSK commits over $800M to expand Pennsylvania operations, adding a biologics manufacturing facility, R&D pilot plant, and 300 jobs.
AB Science Posts €10.4 Million H1 2026 Operating Loss, Names Stéphane Ledermann CEO
AB Science reported an operating loss of €10.4 million for the first half of 2026, compared with a loss of €2.7 million a year earlier, and announced the appointment of Stéphane Ledermann as Chairman and Chief Executive Officer. The wider loss was mainly due to a €6.5 million provision tied to the Research Tax Credit dispute with French tax authorities, following an unfavourable Paris Administrative Court ruling on 22 September 2026; net income came to -€9.0 million versus -€5.2 million in the first half of 2025. Revenue, consisting solely of veterinary drug Masivet sales, was €498 thousand, down slightly from €515 thousand, while cash and cash equivalents stood at €8.9 million as of 30 June 2026, supplemented by €16.5 million raised through private placements in July and August 2026. The company also obtained clinical trial insurance for its Phase 3 amyotrophic lateral sclerosis study with a liability limit of €25 million that can be increased to €39 million, and reported a 67% overall response rate in Stage 3 of the Phase 1 AB8939 plus Venetoclax study in relapsed or refractory acute myeloid leukaemia. AB Science said it expects to resume the Phase 1 acute myeloid leukaemia study in the first quarter of 2027 and the Phase 3 ALS study in the fourth quarter of 2027, and will hold a web conference on 14 October 2026 to present its new roadmap.
AB.PA · Capital · Negative H1 2026 operating loss widened to €10.4M, driven by a €6.5M provision from the unfavorable Research Tax Credit ruling
AB.PA · Technology · Positive Reported 67% overall response rate in Stage 3 of the Phase 1 AB8939 plus Venetoclax AML study and secured clinical trial insurance for the Phase 3 ALS study
Johnson & Johnson Icotyde Shows Two-Year Skin Clearance in Phase 3 Psoriasis Data
Johnson & Johnson said new long-term phase 3 data show its oral drug Icotyde, also known as icotrokinra, maintained high levels of skin clearance in plaque psoriasis patients after more than two years of treatment. In the placebo-controlled ICONIC-LEAD study, at least 72% of patients on the oral IL-23 receptor agonist achieved a Psoriasis Area and Severity Index score of 90, and at least 70% achieved clear or almost clear skin on the Investigator's Global Assessment 0/1 scale, from week 64 through week 112. Complete skin clearance also continued over that period, with at least 44% of Icotyde patients reaching PASI 100 and at least 46% achieving IGA 0, meaning clear skin. Improvements in itch were also seen from week 64 through week 112.
Eli Lilly's Taltz Plus Zepbound Shows Added Psoriasis and Metabolic Benefit in Phase 3b Trial
An exploratory analysis of Eli Lilly's ongoing phase 3b TOGETHER-PsO trial indicates that combining Taltz, or ixekizumab, with Zepbound, or tirzepatide, may improve both psoriasis and metabolic outcomes compared with Taltz alone. The trial enrolled patients with moderate-to-severe plaque psoriasis who were obese or overweight and who had at least one additional weight-related comorbid condition, randomizing them to receive Taltz plus Zepbound or Taltz alone. At week 36, participants who took the two treatments together saw better changes in psoriasis-specific, immune, and metabolic biomarkers than those in the Taltz monotherapy group, with changes noted in more psoriasis disease-associated and metabolic biomarkers. The trial's primary endpoint is the proportion of participants achieving both Psoriasis Area and Severity Index 100 and at least 10% weight reduction at week 36. Lilly noted that in the US, approximately 61% of individuals with psoriasis also have obesity or are overweight with at least one weight-related comorbidity.
Pfizer Wins FDA Approval for Frontline TUKYSA Maintenance in HER2-Positive Breast Cancer
Pfizer has received U.S. FDA approval for TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a chemotherapy-free maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy, expanding the drug into the frontline metastatic setting. The decision moves TUKYSA into an earlier phase of care for a broader patient group and reinforces Pfizer's growing emphasis on targeted oncology therapies, supported by Phase 3 HER2CLIMB-05 data. The approval fits Pfizer's narrative of shifting from a shrinking COVID portfolio toward a more oncology-led, specialty medicine story while keeping its sizeable dividend intact, though on its own it does not meaningfully change near-term dependence on cost savings and execution in obesity and oncology pipelines. Pfizer's narrative projects $54.3 billion in revenue and $9.1 billion in earnings by 2029, implying a 5.2% yearly revenue decline but an earnings increase of about $4.8 billion from $4.3 billion today, with a $28.88 fair value estimate representing 4% upside to the current price. The most relevant supporting development is Pfizer's fresh Phase 3 success with LITFULO in nonsegmental vitiligo, which, like TUKYSA, leans into higher value specialty care, while the recently affirmed US$0.43 quarterly dividend keeps income in focus.
PFE · Regulation · Positive FDA approval expands TUKYSA into the frontline metastatic HER2-positive breast cancer maintenance setting, broadening its patient population.
Johnson & Johnson Q3 Earnings Preview: Estimates Cut, Stelara Biosimilar Pressure Looms
Johnson & Johnson will report its third-quarter 2026 results on Oct. 13, with the Zacks Consensus Estimate pegged at $25.37 billion in sales and $2.66 per share in earnings. Over the past 60 days, the consensus estimate for 2026 earnings has declined from $11.48 to $11.21 per share, while the 2027 estimate has fallen from $12.81 to $12.17. J&J has an Earnings ESP of +2.10% and a Zacks Rank #3 (Hold), and it exceeded earnings expectations in each of the trailing four quarters, delivering an average surprise of 1.39%. Within the Innovative Medicine segment, consensus estimates stand at $4.33 billion for Darzalex, $2.24 billion for Tremfya and $1.07 billion for Erleada, while Stelara sales are seen at $634.0 million and Imbruvica at $602.0 million, with Stelara's loss of exclusivity having cut the segment's growth by 760 basis points in the second quarter. The MedTech segment carries a consensus estimate of $8.77 billion, and J&J still expects to generate more than $100 billion in revenues in 2026 after $49.4 billion in the first half.
JNJ · Capital · Negative Consensus 2026/2027 EPS estimates cut ahead of Q3 report, with Stelara loss of exclusivity dragging Innovative Medicine growth.
Novo Nordisk Raises 2026 Outlook, Targets Peer-Level Growth Through 2030
Novo Nordisk raised its 2026 outlook while telling investors at a London strategy day that it aims to grow revenue through 2030 at roughly the pace of large drugmaker peers. In the second quarter of 2026, adjusted sales rose 7% at constant exchange rates and adjusted operating profit rose 11%, though reported operating profit fell 16%, dragged down by a DKK 6.3 billion non-cash impairment on pipeline assets and by a year-ago rebate reversal. The raised 2026 outlook now puts adjusted sales and operating profit between flat and down 6% at constant exchange rates, while the longer view promises more than five multi-blockbuster launches by 2030, over DKK 150 billion in pipeline sales in 2035, and revenue growth in line with peers from 2026 to 2030, which management stressed are ambitions rather than guidance. The company's Wegovy pill topped 265,000 weekly prescriptions in a single week this summer and total prescriptions have passed 5 million since launch, but Eli Lilly's Mounjaro and Zepbound have overtaken Ozempic and Wegovy in the US, and Novo's next-generation shot CagriSema missed its goal of proving it was not inferior to Lilly's tirzepatide. At a forward P/E of 10.97 as of October 6, against 18.77 for the sector and a five-year average of 27.91, Novo trades well below peers, with 59 hedge funds holding the stock in the most recent quarter, up from 55, and short interest at just 0.83% of the float.
NVO · Capital · Neutral Novo raised its 2026 outlook and reported Q2 adjusted sales +7% and operating profit +11%, but reported operating profit fell 16% on a DKK 6.3bn impairment and the outlook still implies flat-to-down adjusted sales/profit.
NVO · Competition · Negative Eli Lilly's Mounjaro and Zepbound have overtaken Ozempic and Wegovy in the US, and Novo's next-gen CagriSema missed its non-inferiority goal versus Lilly's tirzepatide.
LLY · Competition · Positive Eli Lilly's Mounjaro and Zepbound have overtaken Ozempic and Wegovy in the US, and CagriSema missed its non-inferiority goal versus Lilly's tirzepatide.
Eli Lilly Trades at 30.94 Times Forward Earnings Despite 48% Revenue Growth
Eli Lilly reported 48% revenue growth for the second quarter of 2026 and raised its full-year outlook, yet the stock trades at 30.94 times forward earnings, well below its five-year average of 45.59. Mounjaro brought in $9.9 billion in the quarter, up 91%, and Zepbound added $4.9 billion, up 46%, while non-GAAP gross margin reached 86.3% and revenue outside the US rose 80% to $8.6 billion. The once-daily weight-loss pill Foundayo booked $98 million in its first quarter of sales, and Medicare's new coverage pathway now lets eligible patients get Foundayo or Zepbound for $50 a month, with Lilly estimating about 20 million Medicare patients may meet the clinical criteria. Management lifted 2026 revenue guidance to between $85 billion and $87 billion from $82 billion to $85 billion, and plans to file retatrutide with the FDA in the first quarter of 2027. Growth was volume-led, with volume up 60% against a 13% decline in realized prices, and second-quarter EPS of $8.38 absorbed $3.03 per share of acquired research charges, while reported EPS was $7.94 and full-year guidance stands at $35.50 to $36.50.
LLY · Capital · Positive Lilly reported 48% Q2 revenue growth, 86.3% gross margin, and raised full-year 2026 revenue guidance to $85-87B.
LLY · Demand · Positive Mounjaro sales rose 91% to $9.9B, Zepbound rose 46% to $4.9B, and Medicare's new coverage pathway opens Foundayo/Zepbound to ~20M eligible patients.
FDA Approves Roche's Tecentriq for Stage III dMMR Colon Cancer
The FDA has approved Tecentriq and Tecentriq Hybreza, in combination with fluoropyrimidine and oxaliplatin chemotherapy, for the adjuvant treatment of stage III deficient DNA mismatch repair colon cancer, marking the 12th U.S. indication for Roche's cancer immunotherapy. The decision was based on the phase III ATOMIC study, which enrolled 712 patients with stage III dMMR colon cancer and showed that adding Tecentriq reduced the risk of disease recurrence or death by 50% compared with chemotherapy alone, with a 36-month disease-free survival rate of 86% versus 76% for chemotherapy alone. The approval makes Tecentriq the first approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, and Roche plans additional regulatory filings including a submission to the European Medicines Agency. Tecentriq generated sales of CHF 1.7 billion in the first half of 2026, up 6%. Roche shares have risen 3.5% year to date.
ROP.SW · Regulation · Positive FDA approves Tecentriq as first adjuvant immunotherapy for stage III dMMR colon cancer, expanding Roche's label and sales potential.
Tilray, PepsiCo, Levi Strauss Report Mixed Quarterly Results
Tilray Brands reported a first-quarter fiscal 2027 loss of $0.32 per share, wider than the Zacks Consensus Estimate of a loss of $0.19 per share, sending its shares down 3.4%. PepsiCo reported third-quarter 2026 earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.29 per share, and its shares gained 3.7%. Levi Strauss & Co. reported third-quarter fiscal 2026 revenues of $1,610 million, lagging the Zacks Consensus Estimate of $1,615 million, and its shares tumbled 2.4%. Micron Technology shares fell 4.8% on a broader tech decline.
Eli Lilly Consensus Estimates Rise as Zacks Rank Holds at #3
Eli Lilly is expected to post earnings of $9.83 per share for the current quarter, a year-over-year change of +40%, with the Zacks Consensus Estimate edging up +0.1% over the last 30 days. For the current fiscal year, the consensus earnings estimate of $36.64 points to a change of +51.3% from the prior year and has risen +0.3% over the past month, while the next fiscal year's consensus estimate of $46.8 indicates a change of +27.7% and has moved +1.4% higher. On the revenue side, the consensus sales estimate of $22.14 billion for the current quarter points to a year-over-year change of +25.8%, with the $88.88 billion and $102.02 billion estimates for the current and next fiscal years indicating changes of +36.4% and +14.8%, respectively. In the last reported quarter, Lilly posted revenues of $22.97 billion, up +47.7% year over year, and EPS of $8.38 versus $6.31 a year ago, beating the Zacks Consensus revenue estimate of $20.26 billion by +13.38% and the EPS estimate by +39.43%. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Lilly, and the stock is graded D on the Zacks Value Style Score, indicating it trades at a premium to its peers.
LLY · Capital · Positive Consensus earnings and revenue estimates for Eli Lilly rose, with current-quarter EPS seen up 40% YoY and full-year EPS up 51.3%.
Johnson & Johnson Reports Two-Year ICOTYDE Data in Plaque Psoriasis
Johnson & Johnson announced new two-year results from the Phase 3 ICONIC-LEAD study of ICOTYDE, also known as icotrokinra, the first and only targeted oral peptide that precisely blocks the IL-23 receptor, in adults and adolescents 12 years of age and older with moderate-to-severe plaque psoriasis. The data, presented at Fall Clinical Dermatology 2026, showed that from Week 64 through Week 112 at least 72% of ICOTYDE-treated patients achieved a Psoriasis Area and Severity Index score of 90 and at least 70% achieved clear or almost clear skin on the Investigator's Global Assessment 0/1 scale, with no new safety signals identified. Complete skin clearance was sustained over the same period, with at least 44% of patients achieving PASI 100 and at least 46% achieving IGA 0, while clinically meaningful improvement in itch was sustained in 78% of patients. Among PASI 90 responders withdrawn from ICOTYDE at Week 24, 85% regained PASI 90 response within 24 weeks of retreatment. ICONIC-LEAD is a randomized controlled trial that evaluated ICOTYDE against placebo in 684 participants, of whom 456 received ICOTYDE and 228 received placebo, including 66 adolescent patients. ICOTYDE is approved in the United States for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older weighing at least 40 kg, and is also approved in Europe, Japan and China; it was jointly discovered and is being developed under a license and collaboration agreement between Protagonist and Johnson & Johnson.
JNJ · Technology · Positive Two-year Phase 3 ICONIC-LEAD data show durable PASI 90/100 and IGA responses for ICOTYDE with no new safety signals.
PTGX · Technology · Positive ICOTYDE, jointly discovered and developed with J&J under their license and collaboration agreement, showed sustained two-year efficacy in plaque psoriasis.
Lilly's Taltz Plus Zepbound Shows Broader Biomarker Changes in Psoriasis and Obesity Trial
Eli Lilly and Company announced new exploratory data from the TOGETHER-PsO Phase 3b trial showing that concomitant use of Taltz and Zepbound produced broader biomarker changes than Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. The prespecified analysis, presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, examined circulating proteins and gene expression in the blood and found that Taltz plus Zepbound was associated with changes in more proteins, 482 versus 140 differentially expressed proteins, and more genes, 467 versus 16 differentially expressed genes, by Week 36, with broader biomarker responses emerging as early as Week 12. The combination also showed greater reductions in inflammatory immune activity than Taltz alone, including changes related to neutrophils, and changes in a subset of neutrophil-associated markers mediated a portion of the additional Psoriasis Area and Severity Index response. The data follow previously reported TOGETHER-PsO results showing superior skin clearance and clinically meaningful weight reduction with the combination versus Taltz alone at the Week 36 primary endpoint, maintained or further improved through Week 52, with safety consistent with the known profile of each medicine. In the U.S., approximately 61% of people with psoriasis also have obesity or overweight with at least one weight-related comorbidity.
LLY · Technology · Positive New TOGETHER-PsO Phase 3b biomarker data show Taltz plus Zepbound produced broader biomarker and inflammatory changes than Taltz alone, supporting the combination's clinical profile.
Novo Nordisk Gets FDA Review Update on Denecimig as New CagriSema Data Land
Novo Nordisk reported an FDA review update for its haemophilia A therapy denecimig, including manufacturing-related feedback, in October 2026. The FDA has kept the denecimig review open without giving a new action date, flagging manufacturing issues rather than problems with the FRONTIER efficacy or safety data, though Novo Nordisk says the extended review does not change its 2026 financial outlook. The pharmaceutical group also presented new CagriSema data on brain and metabolic pathway effects in obesity and diabetes at EASD 2026, alongside real-world evidence comparing clinical outcomes for semaglutide with tirzepatide in everyday practice. Novo Nordisk, a US based pharmaceuticals group with a market value of about DKK1.1 trillion, focuses on treatments for chronic conditions such as diabetes, obesity and blood disorders. The key signposts ahead are the EMA decision following the positive CHMP opinion for denecimig and the US FDA decision on the CagriSema obesity filing expected in the fourth quarter of 2026.
NVO · Regulation · Neutral FDA kept the denecimig haemophilia A review open, flagging manufacturing issues with no new action date, though efficacy/safety data were not the problem.
NVO · Technology · Positive New CagriSema data on brain and metabolic pathway effects in obesity and diabetes were presented at EASD 2026, alongside positive CHMP opinion for denecimig.
Citi cuts Novo Nordisk price target to 296 crowns on flat margin outlook
Citi Research lowered its price target on Novo Nordisk to 296 Danish crowns from 310, citing company guidance for broadly stable margins through 2030 that leaves little room for margin growth. The rating was kept at neutral. The guidance, driven by research and development spending, came at Novo's recent capital markets day, prompting Citi to cut its adjusted operating profit forecasts for 2028 to 2030 by 2% to 4%. Citi's target now assumes Novo trades at 14 times 2027 earnings, down from 15 times, and the analysts cut their expected 2027-2030 annual earnings-per-share growth rate to 9% from 12%. Citi raised its 2026 and 2027 adjusted operating profit forecasts by 2% to 3% on higher expected sales of Novo's Wegovy pill outside the United States and U.S. prescription trends for Ozempic, and lifted its adjusted sales forecasts by 3% for 2026 and 1% for 2027. At the capital markets day, Novo said improved manufacturing capacity means it intends to launch the Wegovy pill in at least 20 countries by the end of 2027, covering two-thirds of the obesity market it currently serves, and Citi raised its peak sales forecast for the pill to $13 billion from $10 billion, pointing to its UK launch where 1 million packs have been distributed since July. Ahead of Novo's third-quarter results on Nov. 4, Citi forecast sales 1% above consensus and Wegovy pill sales 16% above it at kr5.3 billion against the consensus kr4.5 billion, with adjusted operating profit in line with consensus because of lower margins from higher R&D spending. Citi forecast third-quarter sales of kr73.5 billion, down 4% at constant currency, citing a roughly kr3 billion rebate-adjustment and stocking benefit in the year-earlier quarter, continued prescription and price declines for U.S. Ozempic, generic launches in Canada and Brazil, and price declines for injectable Wegovy, and said prescription data showed no real impact from Medicare eligibility for GLP-1 drugs. It forecast adjusted operating profit up 18% at constant currency, or down about 15% excluding kr9 billion in year-earlier restructuring charges, and IFRS earnings per share of kr4.15, down 8% from a year earlier mainly on an impairment after the failure of ziltivekimab in the ZEUS trial. Citi said a Wegovy pill beat would be welcome but poor visibility on injectable Wegovy pricing and growing long-term threats from competitors were likely to keep many on the sidelines, naming Lilly's retatrutide and eloralintide, Roche's enicepatide, PFE's MET-097i and AZN's elecoglipron.
NVO · Capital · Negative Citi cut its Novo Nordisk price target to 296 crowns and lowered 2028-2030 operating profit and EPS growth forecasts on flat margin guidance.
China
